Gardner Denver (NYSE:GDI) Cut to Neutral at BTIG Research

Share on StockTwits

Gardner Denver (NYSE:GDI) was downgraded by investment analysts at BTIG Research from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Monday, Marketbeat Ratings reports.

A number of other research firms have also recently weighed in on GDI. Barclays reiterated a “hold” rating and issued a $30.00 target price on shares of Gardner Denver in a research note on Wednesday, September 4th. Zacks Investment Research upgraded shares of Gardner Denver from a “sell” rating to a “hold” rating in a research note on Tuesday, October 29th. ValuEngine upgraded shares of Gardner Denver from a “sell” rating to a “hold” rating in a research note on Tuesday, December 3rd. Credit Suisse Group cut shares of Gardner Denver from an “outperform” rating to a “neutral” rating and boosted their target price for the company from $30.00 to $32.00 in a research note on Wednesday, October 30th. Finally, CIBC reiterated a “hold” rating and issued a $31.00 target price on shares of Gardner Denver in a research note on Monday, August 12th. Eight equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $33.40.

GDI opened at $33.44 on Monday. The company has a quick ratio of 1.60, a current ratio of 2.51 and a debt-to-equity ratio of 0.89. The stock has a market cap of $6.98 billion, a price-to-earnings ratio of 25.92 and a beta of 1.46. Gardner Denver has a twelve month low of $18.70 and a twelve month high of $36.22. The company’s 50-day moving average price is $33.29 and its two-hundred day moving average price is $31.93.

Gardner Denver (NYSE:GDI) last released its earnings results on Monday, October 28th. The company reported $0.20 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.13 by $0.07. The firm had revenue of $596.70 million for the quarter, compared to analysts’ expectations of $622.21 million. Gardner Denver had a net margin of 8.90% and a return on equity of 13.04%. As a group, sell-side analysts anticipate that Gardner Denver will post 0.76 earnings per share for the current year.

In related news, insider Gillard Steven 756,503 shares of the stock in a transaction that occurred on Friday, November 15th. Corporate insiders own 1.70% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Capital Investment Advisory Services LLC purchased a new stake in shares of Gardner Denver during the 2nd quarter valued at approximately $33,000. Quest Capital Management Inc. ADV purchased a new stake in shares of Gardner Denver during the 3rd quarter valued at approximately $34,000. NumerixS Investment Technologies Inc purchased a new stake in shares of Gardner Denver during the 2nd quarter valued at approximately $45,000. Aperio Group LLC purchased a new stake in shares of Gardner Denver during the 2nd quarter valued at approximately $115,000. Finally, FNY Investment Advisers LLC lifted its stake in shares of Gardner Denver by 62.0% during the 3rd quarter. FNY Investment Advisers LLC now owns 6,478 shares of the company’s stock valued at $183,000 after buying an additional 2,478 shares in the last quarter.

About Gardner Denver

Gardner Denver Holdings, Inc provides mission-critical flow control and compression equipment; and associated aftermarket parts, consumables, and services in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Industrials, Energy, and Medical.

Featured Article: What is a Reverse Stock Split?

Analyst Recommendations for Gardner Denver (NYSE:GDI)

Receive News & Ratings for Gardner Denver Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gardner Denver and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.